跳至主要内容
临床试验/NCT02652156
NCT02652156终止3 期

Transversus Abdominis Plane (TAP) Block Study for Postoperative Pain Control

Joshua Herskovic0 个研究点目标入组 14 人开始时间: 2015年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
14
主要终点
Total Dosage of Narcotic

研究概览

简要总结

This clinical trial will examine differences in the effectiveness between three (3) commonly used methods and/or medications used to perform a transversus abdominis plane (TAP) block for post-operative pain control. The transversus abdominis muscle is either side between the lowest rib and the hip bone. Group A subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine injected into the TAP. Group B subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine into the TAP. Group C subjects will be treated with a continuous infusion of the local anesthetic ropivacaine with the ON-Q® pump. There will be no placebo group in this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to give written informed consent
  • Scheduled for open abdominal surgery
  • American Society of Anesthesiologists physical status 1 to 3

排除标准

  • Inability to understand the study or provide written informed consent
  • Inability to follow protocol instructions
  • Complicated history of chronic opioid use including daily use of opioids for a period greater than 2 weeks prior to surgery
  • Allergy to local anesthetic agents
  • Contraindication to regional nerve block such as:
  • Bleeding disorder
  • Infection at site of block
  • Body Mass Index (BMI) >40
  • Pregnancy

研究组 & 干预措施

Single Injection of Bupivacaine

Active Comparator

Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.

干预措施: Bupivacaine (Drug)

Single Injection of Exparel®

Active Comparator

Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane

干预措施: Exparel® (Drug)

Continuous infusion of Ropivacaine

Active Comparator

Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump

干预措施: Ropivacaine (Drug)

结局指标

主要结局

Total Dosage of Narcotic

时间窗: 3 postoperative days

The total use of analgesic medications will be recorded during the 3 days immediately following surgery.

次要结局

  • Number of Days Required for a Patient to Get Out of Bed(Assessed daily for up to 3 days post-surgery)
  • Postoperative Vomiting (Events)(3 postoperative days)
  • Patient Reported Pain by VAS Scale(Postoperative Day 3)
  • Number of Days Required for a Patient to Walk Unassisted(Assessed daily for up to 3 days post-surgery)

研究者

发起方
Joshua Herskovic
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Joshua Herskovic

Anesthesiologist

Midwestern Regional Medical Center

相似试验

TAP Block for Postoperative Pain Control | 临床试验